Effect of aluminum on markers of bone formation resorption in chronic hemodialysis patients

1. Spasovski GB. Bone health and vascular calcification relationships in chronic kidney disease. Int Urol Nephrol. 2007; 39:1209-16.1789943110.1007/s11255-007-9276-9Search in Google Scholar

2. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4 Suppl 3):S1-201.10.1016/S0272-6386(03)00905-3Search in Google Scholar

3. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKDMBD). Kidney Int Suppl. 2009; 113:S1-130.Search in Google Scholar

4. Hutchison AJ, Smith CP, Brenchley PE. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol. 2011; 7:578-89.10.1038/nrneph.2011.112Open DOISearch in Google Scholar

5. D’Haese PC, De Broe M. Aluminum, Lanthanum, and Strontium. Fourth ed: Lippincott Williams & Wilkins; 2006.Search in Google Scholar

6. Kausz AT, Antonsen JE, Hercz G, Pei Y, Weiss NS, Emerson S, et al. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am J Kidney Dis. 1999; 34:688-93.10.1016/S0272-6386(99)70394-XOpen DOISearch in Google Scholar

7. Cannata-Andia JB, Fernandez-Martin JL. The clinical impact of aluminium overload in renal failure. Nephrol Dial Transplant. 2002; 17 Suppl 2:9-12.10.1093/ndt/17.suppl_2.911904351Search in Google Scholar

8. Jaffe JA, Liftman C, Glickman JD. Frequency of elevated serum aluminum levels in adult dialysis patients. Am J Kidney Dis. 2005; 46:316-9.10.1053/j.ajkd.2005.04.02016112051Open DOISearch in Google Scholar

9. Malluche HH. Aluminium and bone disease in chronic renal failure. Nephrol Dial Transplant. 2002; 17 Suppl 2:21-4.10.1093/ndt/17.suppl_2.2111904354Search in Google Scholar

10. D’Haese PC, Couttenye MM, Goodman WG, Lemoniatou E, Digenis P, Sotornik I, et al. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload. Nephrol Dial Transplant. 1995; 10:1874-84.Search in Google Scholar

11. D’Haese PC, Couttenye MM, De Broe ME. Diagnosis and treatment of aluminium bone disease. Nephrol Dial Transplant. 1996; 11 Suppl 3:74-9.10.1093/ndt/11.supp3.748840316Search in Google Scholar

12. Urena P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol. 1996; 7:506-12.10.1681/ASN.V735068704118Search in Google Scholar

13. Urena P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int. 1999; 55:2141-56.10.1046/j.1523-1755.1999.00461.x10354264Open DOISearch in Google Scholar

14. Roe S, Cassidy MJ. Diagnosis and monitoring of renal osteodystrophy. Curr Opin Nephrol Hypertens. 2000; 9:675-81.10.1097/00041552-200011000-00014Search in Google Scholar

15. Morishita T, Nomura M, Hanaoka M, Saruta T, Matsuo T, Tsukamoto Y. A new assay method that detects only intact osteocalcin. Two-step non-invasive diagnosis to predict adynamic bone disease in haemodialysed patients. Nephrol Dial Transplant. 2000; 15:659-67.10.1093/ndt/15.5.659Search in Google Scholar

16. Ferreira A, Drueke TB. Biological markers in the diagnosis of the different forms of renal osteodystrophy. Am J Med Sci. 2000; 320:85-9.10.1097/00000441-200008000-00004Open DOISearch in Google Scholar

17. Bervoets AR, Spasovski GB, Behets GJ, Dams G, Polenakovic MH, Zafirovska K, et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis. 2003; 41:997-1007.10.1016/S0272-6386(03)00197-5Open DOISearch in Google Scholar

18. Ferreira A. Development of renal bone disease. Eur J Clin Invest. 2006; 36 Suppl 2:2-12.10.1111/j.1365-2362.2006.01661.x16884393Open DOISearch in Google Scholar

19. Schwarz C, Sulzbacher I, Oberbauer R. Diagnosis of renal osteodystrophy. Eur J Clin Invest. 2006; 36 Suppl 2:13-22.10.1111/j.1365-2362.2006.01666.x16884394Open DOISearch in Google Scholar

20. Hamano T, Tomida K, Mikami S, Matsui I, Fujii N, Imai E, et al. Usefulness of bone resorption markers in hemodialysis patients. Bone. Jul 2009;45 Suppl 1: S19-25.10.1016/j.bone.2009.03.66319332165Open DOISearch in Google Scholar

21. Mudge DW, Johnson DW, Hawley CM, Campbell SB, Isbel NM, van Eps CL, et al. Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol. 2011; 12:2010.1186/1471-2369-12-20310716921569446Open DOISearch in Google Scholar

22. Gault PM, Allen KR, Newton KE. Plasma aluminium: a redundant test for patients on dialysis? Ann Clin Biochem. 2005; 42:51-4.10.1258/000456305302686215802033Open DOISearch in Google Scholar

23. Arenas MD, Malek T, Gil MT, Moledous A, Nunez C, Alvarez-Ude F. Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era. Nefrologia. 2008; 28:168-73.Search in Google Scholar

24. Pepper R, Campbell N, Yaqoob MM, Roberts NB, Fan SL. Do oral aluminium phosphate binders cause accumulation of aluminium to toxic levels? BMC Nephrol. 2011; 12:55.10.1186/1471-2369-12-55320642021992770Open DOISearch in Google Scholar

25. Kan WC, Chien CC, Wu CC, Su SB, Hwang JC, Wang HY. Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients. Nephrol Dial Transplant. 2010; 25:1604-8.10.1093/ndt/gfp64919948879Search in Google Scholar

26. Bellows CG, Heersche JN, Aubin JE. Aluminum accelerates osteoblastic differentiation but is cytotoxic in long-term rat calvaria cell cultures. Calcif Tissue Int. 1999; 65:59-65.10.1007/s00223990065810369735Open DOISearch in Google Scholar